Forrestania Resources (ASX:FRS) reported a mineral resource estimate of 2 million tonnes at 1.15 grams per tonne grade of gold for 73,800 ounces at a 0.5 g/t grade of gold cut-off for the MacPhersons deposit in Western Australia, according to a Tuesday filing with the Australian bourse.
The company's global JORC-compliant mineral resource estimate now stands at nearly 25.7 million tonnes at 1.22 g/t grade of gold for 1 million gold ounces, the filing said.
Kelsian Group (ASX:KLS) unit Transit Systems West signed a two-year contract extension with Transport for New South Wales for public bus services in the inner west region of Sydney, according to a Tuesday filing with the Australian bourse.Services under the contract will start July 1, with the company securing about AU$500 million in additional revenue over the extension period, per the filing.The contract includes the operation and maintenance of 528 buses from four depots, as well as a fleet replacement program to supply an additional 151 fully electric buses.
Northern Star Resources (ASX:NST) should conduct a strategic review that includes a potential sale, alongside a search for a new CEO, to identify opportunities for operational improvements, shareholder Elliott Investment Management said Monday.Elliott disclosed a stake of over AU$1 billion in Northern Star Resources, saying it wants to work with the company to maximize shareholder value."Northern Star's recent pattern of operational missteps, cost overruns and inconsistent strategic direction demands urgent action," Elliott said, adding that the company has underperformed its potential despite holding world-class gold assets.The activist investor also urged the company to supplement its board with "fresh perspectives" to help guide the review and subsequent steps.Elliott further alleged that Northern Star has "deeply inadequate disclosures compared to global senior peers." The company is likely to draw "significant strategic interest" if it explores a sale, Elliott said.Northern Star Resources did not immediately reply to a request for comment from.
ResMed (ASX:RMD) completed its acquisition of Noctrix Health, a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders, according to a Tuesday statement by the company.The acquisition broadens the company's clinical sleep health portfolio into an adjacent area with significant unmet need, focusing on the treatment of restless legs syndrome, the third most prevalent sleep disorder.The deal includes Noctrix's US Food and Drug Administration de novo-cleared Nidra tonic motor activation therapy, a clinically validated treatment that reduces restless leg syndrome symptoms and improves sleep quality in patients unresponsive to drug therapies.The company said the acquisition supports its 2030 strategy to scale connected home sleep and health solutions.